Overview / Abstract: |
Target Audience This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses. Program Overview New treatments for advanced pancreatic cancer are leading to better outcomes and allowing patients to go on maintenance therapy. In this activity, an expert panel reviews recent clinical evidence and guideline-based selection of appropriate therapies. The case-based discussion covers germline and somatic testing for biomarkers, selection of first- and later-line agents, novel and emerging therapies, and management of disease-related symptoms and treatment-related adverse events. Use of an individualized approach and improving patient adherence and are also emphasized. Learning Objectives Upon completion of this activity, participants should be better able to: Summarize recent findings on the use of biomarkers in pancreatic cancer |
Expiration |
Mar 19, 2022 |
Format |
Online |
Credits / Hours |
CE/CME Credit Hours: 1.00 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty FACULTY_NAME FACULTY_NAME FACULTY_NAME FACULTY_NAME |
Sponsors / Supporters / Grant Providers |
AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck & Co., Inc.; and Taiho Oncology, Inc. Bristol-Meyers Squibb. |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME.,Advanced Pancreatic Cancer Free CE CME |